Immunoglobulin gamma-1 heavy chain
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 12 PDB declaration: dodecameric（12） Consistent with protein copy count | Chain A； UniProt 223–443 Chain B； UniProt 223–443 Chain C； UniProt 223–443 Chain D； UniProt 223–443 Chain E； UniProt 223–443 Chain F； UniProt 223–443 Chain G； UniProt 223–443 Chain H； UniProt 223–443 Chain I； UniProt 223–443 Chain J； UniProt 223–443 Chain K； UniProt 223–443 Chain L； UniProt 223–443 | Not recorded | No other associated polymer | ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：Cryogen ETHANE | Resolution 3.70 Å |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 7X13 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1D5B UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25%PEG 1000, 100mM sodium acetate, 300mM CdCl2, 100mM ammonium sulfate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.285 |
| 1D5B UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25%PEG 1000, 100mM sodium acetate, 300mM CdCl2, 100mM ammonium sulfate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.285 |
| 1D5B UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25%PEG 1000, 100mM sodium acetate, 300mM CdCl2, 100mM ammonium sulfate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.285 |
| 1D5I UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；75mM Hepes pH 7.0 9% PEG 4000 150 mM Ammonium Sulfate 20% 1,4 butanediol 100 mM Cadmium Chloride, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.263 |
| 1D6V CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION Deposited 1999-10-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 4 HOP (1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；292 K；9% polyethylene glycol 4000 250mM ammonium sulfate 80mM Cadmium Chloride 75mM Hepes 20% 1,4 butanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 19K
|
Resolution 2.00 Å R-free 0.264 |
| 1HZH CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN Deposited 2001-01-24 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
117–449（333 aa）
Chain K
117–449（333 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295.5 K；NH4SO4, cacodylate, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 295.5K
|
Resolution 2.70 Å R-free 0.273 |
| 1N0X Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope Deposited 2002-10-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain H
117–222（106 aa）
Fragment：UNP residues 117-222
Chain K
117–222（106 aa）
Fragment：UNP residues 117-222
|
Not recorded | GOL GLYCEROL × 8 SO4 SULFATE ION × 4 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 1 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 10.5；295.5 K；ammonium sulfate, lithium sulfate, CAPS buffer, pH 10.5, VAPOR DIFFUSION, SITTING DROP, temperature 295.5K
|
Resolution 1.80 Å R-free 0.252 |
| 3PGF Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (sAB) Deposited 2010-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
121–227（107 aa）
|
Not recorded | IMD IMIDAZOLE × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；292 K；19% PEG 3400, 8% Tacsimate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 2.10 Å R-free 0.227 |
| 4R26 Crystal structure of human Fab PGT124, a broadly neutralizing and potent HIV-1 neutralizing antibody Deposited 2014-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
115–223（109 aa）
|
Not recorded | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% PEG 4000, 0.2M MgCl2, 0.1M Tris-HCL, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.267 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain Q
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain J
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain N
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 5O4E Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6 Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
Chain C
227–448（222 aa）
Chain D
227–449（223 aa）
|
Mutation：T350V, T366L, K392L, T394W Mutation：;T350V, L351Y, T359R, K360F, N361Y, E388D, N389I, F389a, P389b, N389c, G389d, L389e, F405A, Y407V, D413P, K414Y, S415P, R416S, Q418L, Q419M, N421T, V422R, S440H, S442E, L443Y, S444Q, P445W, G446P, K447T ; Mutation：T350V, T366L, K392L, T394W Mutation：;T350V, L351Y, T359R, K360F, N361Y, E388D, N389I, F389a, P389b, N389c, G389d, L389e, F405A, Y407V, D413P, K414Y, S415P, R416S, Q418L, Q419M, N421T, V422R, S440H, S442E, L443Y, S444Q, P445W, G446P, K447T ; | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 10 MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1 CAC CACODYLATE ION × 2 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；0.1 M Sodium cacodylate,
40% (v/v) MPD,
5% (w/v) PEG 8000
|
Resolution 2.15 Å R-free 0.236 |
| 5VJ6 BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195 Deposited 2017-04-18 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 14 PDB declaration: tetradecameric |
Chain H
117–224（108 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 11.50 Å |
| 5VU0 Crystal structure of the complex between afucosylated/galactosylated human IgG1 Fc and Fc gamma receptor IIIa (CD16A) with Man5 N-glycans Deposited 2017-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
230–446（217 aa）
Fragment：Fc region (UNP residues 230-446)
Chain B
230–446（217 aa）
Fragment：Fc region (UNP residues 230-446)
|
Not recorded | EDO 1,2-ETHANEDIOL × 5 PEG DI(HYDROXYETHYL)ETHER × 4 NA SODIUM ION × 9 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM Bis-Tris Propane pH 7.5, 16% PEG 20k, 100 mM Potassium thiocyanate, Cryo protection - 20% Ethylene Glycol
|
Resolution 2.26 Å R-free 0.237 |
| 5VZX Crystal structure of crenezumab Fab Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
115–227（113 aa）
Chain H
115–227（113 aa）
|
Not recorded | SO4 SULFATE ION × 11 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.4 M ammonium sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.230 |
| 5VZX Crystal structure of crenezumab Fab Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
115–227（113 aa）
|
Not recorded | SO4 SULFATE ION × 6 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.4 M ammonium sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.230 |
| 5VZX Crystal structure of crenezumab Fab Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
115–227（113 aa）
|
Not recorded | SO4 SULFATE ION × 5 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.4 M ammonium sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.230 |
| 5VZY Crystal structure of crenezumab Fab in complex with Abeta Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
115–227（113 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M magnesium chloride hexahydrate, 0.1 M Tris hydrochloride pH 8.5, 30% w/v polyethylene glycol 4000
|
Resolution 2.32 Å R-free 0.249 |
| 5W5L Crystal structure of human IgG1-Sigma Fc fragment Deposited 2017-06-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
227–449（223 aa）
Fragment：Sigma Fc fragment, UNP residues 227-449
Chain B
227–449（223 aa）
Fragment：Sigma Fc fragment, UNP residues 227-449
|
Mutation：L234A, L235A, A237G, P238S, H268A, A330S, P331S Mutation：L234A, L235A, A237G, P238S, H268A, A330S, P331S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；9% PEG 20,000, 0.1 M Sodium Acetate, pH 5.5
|
Resolution 1.90 Å R-free 0.229 |
| 5WAV Fc AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery. Deposited 2017-06-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
240–448（209 aa）
Chain B
240–448（209 aa）
|
Not recorded | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；0.1M Hepes pH7.5
10% v/v polyethylene glycol 8000
8% v/v ethylene glycol
|
Resolution 2.60 Å R-free 0.260 |
| 5XJE Crystal structure of fucosylated IgG1 Fc complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa Deposited 2017-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
Chain B
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；12% PEG 20000, 0.1 M MES (pH 6.5), 4% Zwittergent 3-12
|
Resolution 2.40 Å R-free 0.281 |
| 5XJF Crystal structure of fucosylated IgG Fc Y296W mutant complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa Deposited 2017-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
Chain B
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
|
Mutation：Y298W Mutation：Y298W | CL CHLORIDE ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；12% PEG 20000, 0.1 M MES (pH 6.5), 4% Zwittergent 3-14
|
Resolution 2.50 Å R-free 0.270 |
| 5XMH Crystal structure of an IgM rheumatoid factor YES8c in complex with IgG1 Fc Deposited 2017-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
239–446（208 aa）
Fragment：UNP RESIDUES 239-446
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Tris-HCl, sodium acetate, PEG 4000
|
Resolution 2.80 Å R-free 0.272 |
| 5XMH Crystal structure of an IgM rheumatoid factor YES8c in complex with IgG1 Fc Deposited 2017-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
239–446（208 aa）
Fragment：UNP RESIDUES 239-446
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Tris-HCl, sodium acetate, PEG 4000
|
Resolution 2.80 Å R-free 0.272 |
| 5Y56 Fc mutant (K392D/K409D/D399K) Deposited 2017-08-07 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–445（208 aa）
Fragment：UNP residues 238-445
Chain B
238–445（208 aa）
Fragment：UNP residues 238-445
|
Mutation：K392D/K409D/D399K Mutation：K392D/K409D/D399K | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1.5M (NH4)2SO4, 10% Glycerol, 0.1M Tris-Hcl (pH 7.5)
|
Resolution 2.65 Å R-free 0.298 |
| 5YC5 Crystal structure of human IgG-Fc in complex with aglycan and optimized Fc gamma receptor IIIa Deposited 2017-09-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
226–448（223 aa）
Fragment：Fc fragment, UNP residues 226-448
Chain B
226–448（223 aa）
Fragment：Fc fragment, UNP residues 226-448
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293.15 K；20mM Tris-HCl, 100mM NaCl, 14% PEG 3350
|
Resolution 2.71 Å R-free 0.273 |
| 6APD Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425 Deposited 2017-08-17 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 15 PDB declaration: pentadecameric |
Chain J
109–223（115 aa）
Chain K
109–223（115 aa）
Chain N
109–223（115 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；10% PEG 4000
10% 2-propanol
0.1 M sodium citrate pH 5.5
|
Resolution 4.10 Å R-free 0.256 |
| 6ARP Structure of a mutant Cetuximab Fab fragment Deposited 2017-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
120–222（103 aa）
|
Not recorded | SO4 SULFATE ION × 3 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol
|
Resolution 1.70 Å R-free 0.197 |
| 6ARP Structure of a mutant Cetuximab Fab fragment Deposited 2017-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
120–222（103 aa）
|
Not recorded | SO4 SULFATE ION × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol
|
Resolution 1.70 Å R-free 0.197 |
| 6ARU Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain Deposited 2017-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
120–222（103 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；150 mM ammonium sulfate, 16.5% PEG3350, 10 mM cadmium chloride, 100 mM imidazole, 5% glycerol
|
Resolution 3.20 Å R-free 0.267 |
| 6B70 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain and insulin Deposited 2017-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton and homemade plunger
|
Resolution 3.70 Å |
| 6B7Z Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11 heavy chain and FAB H11 light chain Deposited 2017-10-05 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton
|
Resolution 6.50 Å |
| 6BF7 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain Deposited 2017-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton
|
Resolution 6.50 Å |
| 6BF9 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain Deposited 2017-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton
|
Resolution 7.20 Å |
| 6BFT Structure of Bevacizumab Fab mutant in complex with VEGF Deposited 2017-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
120–227（108 aa）
Chain H
120–227（108 aa）
|
Not recorded | SO4 SULFATE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；100 mM MES, 6.0, 225 mM ammonium sulfate, 13% PEG4000, 10% isopropanol
|
Resolution 2.55 Å R-free 0.220 |
| 6BGT Structure of Trastuzumab Fab mutant in complex with Her2 extracellular domain Deposited 2017-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；293 K；100 mM MES, pH 6.5, 18% PEG3350, 10% glycerol
|
Resolution 2.70 Å R-free 0.247 |
| 6BKB Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3A Deposited 2017-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；20% (w/v) PEG 3500, 0.2M sodium-citrate
|
Resolution 2.80 Å R-free 0.267 |
| 6BKC Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3B Deposited 2017-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.7；293 K；20% (w/v) PEG 3500, 0.2M Li-chloride
|
Resolution 2.60 Å R-free 0.276 |
| 6BZ4 Human IgG1 lacking complement-dependent cytotoxicity: hu3S193 Fc mutant K322A Deposited 2017-12-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Chain B
239–446（208 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；PEG 6000, 0.1 M MES, 25% V/V ETHYLENE GLYCOL
|
Resolution 2.40 Å R-free 0.249 |
| 6DKJ human GIPR ECD and Fab complex Deposited 2018-05-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–222（114 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10% PEG 4000 and 20% isopropanol
|
Resolution 1.95 Å R-free 0.238 |
| 6DKJ human GIPR ECD and Fab complex Deposited 2018-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
109–222（114 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10% PEG 4000 and 20% isopropanol
|
Resolution 1.95 Å R-free 0.238 |
| 6EAQ Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc Deposited 2018-08-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–446（220 aa）
Chain B
227–446（220 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；pH 6.0 50 mM MES, 8% PEG3350 and 60 mM NaCl
|
Resolution 2.22 Å R-free 0.244 |
| 6FCZ Model of gC1q-Fc complex based on 7A EM map Deposited 2017-12-21 | Different construct Different mutation/modification Different oligomeric state Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain H
234–449（216 aa）
Fragment：UNP residues 234-449
Chain K
234–449（216 aa）
Fragment：UNP residues 234-449
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 10.00 Å |
| 6FGO Fc in complex with engineered calcium binding domain Z Deposited 2018-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
239–448（210 aa）
Chain C
239–448（210 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 5 GOL GLYCEROL × 7 CA CALCIUM ION × 2 CL CHLORIDE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；24 % PEG3350, 0.1 M LiCl2, 0.1 M MES pH 6.0
|
Resolution 2.50 Å R-free 0.232 |
| 6FGO Fc in complex with engineered calcium binding domain Z Deposited 2018-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
239–448（210 aa）
Chain D
239–448（210 aa）
|
Not recorded | GOL GLYCEROL × 8 CA CALCIUM ION × 2 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；24 % PEG3350, 0.1 M LiCl2, 0.1 M MES pH 6.0
|
Resolution 2.50 Å R-free 0.232 |
| 6G1E BEAT Fc with improved heterodimerization (Q3A-D84.4Q) Deposited 2018-03-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
223–449（227 aa）
|
Mutation：L234A, L235A, Q347E, Y349A, L351F, S364T, T366V, K370T, T394D, V397L, D399E, D401Q, F405A, Y407S, K409R, T411R Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；CRYSTALS GROWN BY VAPOR DIFFUSION BY MIXING 12.0 MG/ML PROTEIN IN 10 MM HEPES PH8.0, 100 MM NACL, 1 MM EDTA, EQUALLY WITH 33.00 %(W/V) PEG 1500
|
Resolution 1.88 Å R-free 0.272 |
| 6IFJ Structure of bispecific Fc Deposited 2018-09-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Mutation：E357K,K409R Mutation：K370E | GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291.15 K；0.1M Hepes, pH7.5, 12%(w/v) polyethylene glycol 3350
|
Resolution 2.40 Å R-free 0.231 |
| 6IQG X-ray crystal structure of Fc and peptide complex Deposited 2018-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
238–447（210 aa）
Chain B
238–447（210 aa）
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；PEG 3350, KI
|
Resolution 3.00 Å R-free 0.273 |
| 6IQH X-ray crystal structure of covalent-bonded complex of Fc and peptide Deposited 2018-11-08 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
238–447（210 aa）
Chain B
238–447（210 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10；293 K；0.1 M CHES pH 10.0, 0.3M NaCl, 20% (w/v) PEG 8000
|
Resolution 3.00 Å R-free 0.293 |
| 6KA7 The complex structure of Human IgG Fc and its binding Repebody Deposited 2019-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
240–447（208 aa）
Chain D
240–447（208 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Tris HCl, PEG 4000, Sodium chloride
|
Resolution 3.00 Å R-free 0.333 |
| 6MB3 Cryo-EM structure of the circumsporozoite protein of Plasmodium falciparum with a vaccine-elicited antibody reveals maturation of inter-antibody contacts Deposited 2018-08-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 19 PDB declaration: nonadecameric |
Chain A
109–223（115 aa）
Chain B
109–223（115 aa）
Chain C
109–223（115 aa）
Chain D
109–223（115 aa）
Chain F
109–223（115 aa）
Chain G
109–223（115 aa）
Chain H
109–223（115 aa）
Chain I
109–223（115 aa）
Chain J
109–223（115 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.37 Å |
| 6MSY Anti-HIV-1 Fab Fab 2G12 + Man4 re-refinement Deposited 2018-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–221（102 aa）
|
Not recorded | UNX UNKNOWN LIGAND × 8 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；295 K；27% Peg 4000, 0.05M sodium acetate
|
Resolution 2.00 Å R-free 0.242 |
| 6MU3 Anti-HIV-1 Fab 2G12 + Man7 re-refinement Deposited 2018-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–221（102 aa）
Chain M
120–221（102 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；295 K；20% Peg 4000, 0.2M sodium tartrate
|
Resolution 2.33 Å R-free 0.234 |
| 6MUB Anti-HIV-1 Fab 2G12 + Man5 re-refinement Deposited 2018-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–222（103 aa）
Chain M
120–222（103 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；295 K；1.6M sodium/potassium phosphate
|
Resolution 2.50 Å R-free 0.280 |
| 6N2X Anti-HIV-1 Fab 2G12 + Man9 re-refinement Deposited 2018-11-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–220（101 aa）
Chain M
120–220（101 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；25% Peg 400, 0.2M imidazole malate
|
Resolution 3.00 Å R-free 0.283 |
| 6N32 Anti-HIV-1 Fab 2G12 re-refinement Deposited 2018-11-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–221（102 aa）
Chain K
120–221（102 aa）
|
Not recorded | SO4 SULFATE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；298 K；1.05M ammonium sulfate, 18% Peg 6000, 0.1M imidazole malate
|
Resolution 2.20 Å R-free 0.227 |
| 6N35 Anti-HIV-1 Fab 2G12 + Man1-2 re-refinement Deposited 2018-11-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–220（101 aa）
Chain M
120–220（101 aa）
|
Not recorded | BEZ BENZOIC ACID × 1 GOL GLYCEROL × 1 MAN alpha-D-mannopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2M Sodium/Potassium Phosphate
|
Resolution 1.75 Å R-free 0.238 |
| 6OGE Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex Deposited 2019-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.36 Å |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
109–226（118 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
109–226（118 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
109–226（118 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6UBI N123-VRC34.05 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 Deposited 2019-09-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
117–226（110 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES, pH 7, 30% PEG6000
|
Resolution 1.90 Å R-free 0.288 |
| 6UBI N123-VRC34.05 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 Deposited 2019-09-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
117–226（110 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES, pH 7, 30% PEG6000
|
Resolution 1.90 Å R-free 0.288 |
| 6UGW Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a C-centered orthorhombic crystal form, Lot A Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
220–449（230 aa）
Fragment：LotA_Fc
|
Not recorded | ZN ZINC ION × 6 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；10 mg/mL protein with JCSG+ E7 (266849e7): 10% 2-propanol, 200 mM zinc acetate, 100 mM sodium cacodylate, pH 6.5, cryoprotectant: 20% ethylene glycol, puckID kux1-2
|
Resolution 2.00 Å R-free 0.219 |
| 6UGX Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a primative orthorhombic crystal form, Lot A Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
220–449（230 aa）
Chain B
220–449（230 aa）
|
Not recorded | K POTASSIUM ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；10 mg/mL protein with 200 mM potassium nitrate, 20% PEG3350, cryoprotectant: 20% ethylene glycol, puckID sxt1-6
|
Resolution 2.10 Å R-free 0.256 |
| 6UGY Crystal structure of the Fc fragment of anti-TNFa antibody infliximab (Remicade) in a primative orthorhombic crystal form, Lot C Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
220–449（230 aa）
Fragment：LotC_Fc
|
Not recorded | ZN ZINC ION × 6 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；10 mg/mL protein with JCSG+ E7 Opt screen H2 (267146h2): 4% 2-propanol, 200 mM zinc acetate, 100 mM sodium cacodylate, pH 6.8, cryoprotectant: 20% ethylene glycol, puckID kux1-9
|
Resolution 2.10 Å R-free 0.228 |
| 6UOE 3-25 Fab germline-reversion variant bound to an HCMV gB-derived peptide Deposited 2019-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–223（115 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1 M magnesium chloride, 13.4% PEG3350, 16.75% PEG400, 0.1 M Tris, pH 8.5
|
Resolution 1.80 Å R-free 0.186 |
| 6V8Z VRC03 and 10-1074 Bound BG505 F14 HIV-1 SOSIP Envelope Trimer Structure Deposited 2019-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 18 PDB declaration: octadecameric |
Chain C
117–220（104 aa）
Chain I
117–220（104 aa）
Chain O
117–220（104 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 21 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å |
| 6VSL Crystal structure of a human fucosylated IgG1 Fc expressed in tobacco plants (Nicotiana benthamiana) Deposited 2020-02-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
Chain B
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
|
Not recorded | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；15% PEG4000, 0.1 M HEPES, pH 7.0
|
Resolution 2.10 Å R-free 0.250 |
| 6VSZ Crystal structure of a human afucosylated IgG1 Fc expressed in tobacco plants (Nicotiana benthamiana) Deposited 2020-02-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
Chain B
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；15% PEG4000, 0.1 M HEPES, pH 7.0
|
Resolution 2.60 Å R-free 0.276 |
| 6X3I NNAS Fc mutant Deposited 2020-05-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
227–449（223 aa）
Fragment：Fc
|
Not recorded | BMA beta-D-mannopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；30% polyethylene glycol 1500
|
Resolution 2.27 Å R-free 0.221 |
| 6YSC GLYCOSYLATED KNOB-HOLE/DUMMY FC FRAGMENT Deposited 2020-04-22 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–449（227 aa）
Chain B
223–449（227 aa）
|
Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；294 K；15% (w/v) PEG4000, 0.1M HEPES
|
Resolution 2.05 Å R-free 0.293 |
| 6YT7 GLYCOSYLATED KNOB/DUMMY-HOLE FC FRAGMENT Deposited 2020-04-24 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–449（227 aa）
|
Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；294 K；25% (w/v) PEG2000 MME, 0.1M HEPES
|
Resolution 1.55 Å R-free 0.273 |
| 6YTB GLYCOSYLATED KNOB/DUMMY-HOLE/DUMMY FC FRAGMENT Deposited 2020-04-24 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–449（227 aa）
Chain B
223–449（227 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；20% (w/v) PEG3350, 0.2M potassium formate
|
Resolution 1.65 Å R-free 0.249 |
| 7CZQ S protein of SARS-CoV-2 in complex bound with P2B-1A10 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 7 PDB declaration: heptameric |
Chain H
115–449（335 aa）
Chain J
115–449（335 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 7CZT S protein of SARS-CoV-2 in complex bound with P5A-2G9 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 7 PDB declaration: heptameric |
Chain H
109–449（341 aa）
Chain I
109–449（341 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å |
| 7CZU S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 7 PDB declaration: heptameric |
Chain H
109–449（341 aa）
Chain J
109–449（341 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7CZV S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 9 PDB declaration: nonameric |
Chain H
109–449（341 aa）
Chain I
109–449（341 aa）
Chain J
109–449（341 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 31 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 540 PDB declaration: 540-meric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 9 PDB declaration: nonameric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 45 PDB declaration: 45-meric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 54 PDB declaration: 54-meric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 9 PDB declaration: nonameric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7URU Crystal structure of the low affinity Fc gamma receptor IIIA variant in complex with the Fc of IgG1. Deposited 2022-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；8% PEG 8000
0.1 M HEPES pH 7.0
|
Resolution 2.40 Å R-free 0.262 |
| 8DAO Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV44-79 Deposited 2022-06-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain E
120–222（103 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M Tris, pH 8.5, 0.01 M nickel (II) chloride, and 20% PEG monomethyl ether 2000
|
Resolution 2.80 Å R-free 0.284 |
| 8DAO Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV44-79 Deposited 2022-06-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain G
120–222（103 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M Tris, pH 8.5, 0.01 M nickel (II) chloride, and 20% PEG monomethyl ether 2000
|
Resolution 2.80 Å R-free 0.284 |
| 8DBZ CryoEM structure of Hantavirus ANDV Gn(H) protein complex with 2Fabs ANDV-5 and ANDV-34 Deposited 2022-06-15 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 9 PDB declaration: nonameric |
Chain F
120–222（103 aa）
Fragment：UNP residues 120-222
Chain H
120–222（103 aa）
Fragment：UNP residues 120-222
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.10 Å |
| 8DV1 SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to linker variant of affinity matured ACE2 mimetic CVD432 Deposited 2022-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
218–449（232 aa）
|
Mutation：K31F,N33D,H34S,E35Q | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 8DV2 SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to computationally engineered ACE2 mimetic CVD293 Deposited 2022-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
218–449（232 aa）
|
Mutation：K31F,H34I,E35Q | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å |
| 8ECQ Bovine Fab 2G3 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
115–222（108 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 3 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277.15 K；10% glycerol, 0.1M Mes, 5% Peg1000, 30% Peg600
|
Resolution 2.00 Å R-free 0.253 |
| 8ECV Bovine Fab 2F12 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
114–222（109 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293.15 K；0.2M sodium chloride, 0.1M phosphate-citrate buffer, 20% Peg6000
|
Resolution 1.81 Å R-free 0.261 |
| 8ECV Bovine Fab 2F12 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
114–222（109 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293.15 K；0.2M sodium chloride, 0.1M phosphate-citrate buffer, 20% Peg6000
|
Resolution 1.81 Å R-free 0.261 |
| 8ECZ Bovine Fab 4C1 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
114–222（109 aa）
|
Not recorded | PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1M Tris, 50% MPD, 0.2M ammonium dihydrogen phosphate
|
Resolution 2.82 Å R-free 0.258 |
| 8ECZ Bovine Fab 4C1 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
114–222（109 aa）
|
Not recorded | PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1M Tris, 50% MPD, 0.2M ammonium dihydrogen phosphate
|
Resolution 2.82 Å R-free 0.258 |
| 8ED1 Bovine Fab 5C1 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
114–222（109 aa）
|
Not recorded | GOL GLYCEROL × 3 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277.15 K；0.1M Tris, 10% glycerol, 20% Peg300, 5% Peg8000
|
Resolution 2.31 Å R-free 0.267 |
| 8EDF Bovine Fab SKD in complex with Sars COV-2 receptor binding domain Deposited 2022-09-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
114–222（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293.15 K；0.4M Lithium chloride, 10% Peg6000, 0.1M sodium citrate
|
Resolution 3.40 Å R-free 0.299 |
| 8GHR Structure of human ENPP1 in complex with variable heavy domain VH27.2 Deposited 2023-03-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Not recorded | ZN ZINC ION × 4 AMP ADENOSINE MONOPHOSPHATE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 CA CALCIUM ION × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；phosphate buffered saline
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å |
| 8TTM IgG1 Fc Heterodimer combYSelect1 Deposited 2023-08-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Mutation：K409S, T411Y Mutation：L368S, D399Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；292 K；0.1M BisTris pH 6.5 and 21% PEG MME 5000
|
Resolution 2.51 Å R-free 0.242 |
| 8TUD IgG1 Fc Heterodimer combYSelect2 Deposited 2023-08-16 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Mutation：D399Y, K447S Mutation：K409S, T411Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；292 K；0.1M Bis Tris pH 6.5 and 29% PEG MME 2000
|
Resolution 3.00 Å R-free 0.285 |
| 8URO Crystal structure of IgG1-Fc fragment (E382S) in complex with Corynebacterial ENGase CU43 (D187A-E189A) Deposited 2023-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
218–449（232 aa）
Chain C
218–449（232 aa）
|
Mutation：E382S Mutation：E382S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium acetate 0.1 M MES 6.5 30 %v/v Glycerol ethoxylate (MIDAS 2-31)
|
Resolution 3.62 Å R-free 0.369 |
| 8URO Crystal structure of IgG1-Fc fragment (E382S) in complex with Corynebacterial ENGase CU43 (D187A-E189A) Deposited 2023-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain E
218–449（232 aa）
Chain F
218–449（232 aa）
|
Mutation：E382S Mutation：E382S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium acetate 0.1 M MES 6.5 30 %v/v Glycerol ethoxylate (MIDAS 2-31)
|
Resolution 3.62 Å R-free 0.369 |
| 8W4L Crystal structure of closed conformation of human immunoglobulin Fc in presence of EndoSz Deposited 2023-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100 mM MES PH 6.0
200 mM Zinc acetate
10 % PEG 8000
|
Resolution 3.10 Å R-free 0.257 |
| 8W4M Crystal structure of open conformation of human immunoglobulin Fc in presence of EndoSz Deposited 2023-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
227–449（223 aa）
|
Not recorded | ZN ZINC ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100 mM MES PH 6.5
200 mM Zinc acetate
10 % PEG 8000
|
Resolution 2.18 Å R-free 0.255 |
| 8ZCK Serial Femtosecond Crystallography Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-04-30 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.00 Å R-free 0.227 |
| 8ZCL Ambient Temperature Crystal Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-04-30 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.60 Å R-free 0.236 |
| 8ZCM Cryogenic Temperature Crystal Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.64 Å R-free 0.409 |
| 9BEX X-ray crystallography structural model of the immunoglobulin G1 (IgG1) Fc D270C K326C variant Deposited 2024-04-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain AAA
218–449（232 aa）
Chain BBB
218–449（232 aa）
|
Mutation：D270C,K326C Mutation：D270C,K326C | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1M HEPES pH 7.5, 10% PEG 3350
|
Resolution 2.25 Å R-free 0.302 |
| 9CRT Crystal structure of IgG1 FC at natural pH Deposited 2024-07-22 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；0.1 M Hepes pH 7.5 and 20% PEG 20,000
|
Resolution 2.19 Å R-free 0.282 |
| 9CXL Crystal structure of IgG1 FC WT at pH 5.5 Deposited 2024-07-31 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；1 M Ammonium sulfate, 0.1 M Sodium citrate pH 5.5
|
Resolution 2.33 Å R-free 0.279 |
| 9CY6 Crystal structure of IgG1 FC M252H at pH 7.5 Deposited 2024-08-01 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252H Mutation：M252H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1 M Bis-tris propane pH 7.5, and 8% PEG8K
|
Resolution 2.06 Å R-free 0.282 |
| 9D06 Crystal structure of IgG1 FC M252R at pH 5.6 Deposited 2024-08-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252R Mutation：M252R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；0.1M Sodium citrate pH 5.6, 20% Propanol and 20% PEG 4K
|
Resolution 2.33 Å R-free 0.279 |
| 9D09 Crystal structure of IgG1 FC M252H at pH 5.6 Deposited 2024-08-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252H Mutation：M252H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；0.1M Sodium citrate pH 5.6, 20% Propanol and 20% PEG 4000
|
Resolution 2.92 Å R-free 0.283 |
| 9D9Q Crystal structure of IgG1 FC M252R at pH 8.0 Deposited 2024-08-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252R Mutation：M252R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1 M Tris pH 8.0 and 0.08M Sodium formate and 7.5% PEG20K
|
Resolution 2.82 Å R-free 0.367 |
| 9DAZ Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirus. Complex of fAPN with FCoV-23 RBD Deposited 2024-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
218–449（232 aa）
Chain C
218–449（232 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 ZN ZINC ION × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.50 Å |
| 9IIE Cryogenic Temperature Crystal Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-06-20 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 3.14 Å R-free 0.309 |
| 9K2Y Human IgG1 Fc fragments, mutant (2CT1.1) Deposited 2024-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
Chain C
227–449（223 aa）
Chain D
227–449（223 aa）
|
Not recorded | GAL beta-D-galactopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；50mM Sodium phosphate pH 7.0, 16% PEG 3350
|
Resolution 3.12 Å R-free 0.281 |
| 9K34 Human IgG1 Fc fragments, mutant (2CT1.9) Deposited 2024-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
Chain C
227–449（223 aa）
Chain D
227–449（223 aa）
|
Not recorded | FUL beta-L-fucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；50mM HEPES pH 7.0, 10% PEG 3350
|
Resolution 3.00 Å R-free 0.279 |
| 9KHH Structure of the complex of LGR4 with Norrin (2:2) Deposited 2024-11-10 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 6 PDB declaration: hexameric |
Chain E
220–449（230 aa）
Chain F
220–449（230 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.65 Å |
| 9LOC Cryo-EM structure of human FcRL5 bound to IgG-Fc Deposited 2025-01-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 13 PDB declaration: 13-meric |
Chain B
218–443（226 aa）
Chain C
218–443（226 aa）
Chain D
218–443（226 aa）
Chain E
218–443（226 aa）
Chain F
218–443（226 aa）
Chain G
218–443（226 aa）
Chain H
218–443（226 aa）
Chain I
218–443（226 aa）
Chain J
218–443（226 aa）
Chain K
218–443（226 aa）
Chain L
218–443（226 aa）
Chain M
218–443（226 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 13 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.56 Å |
| 9LOD Local structure of human FcRL5 bound to IgG-Fc Deposited 2025-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain B
218–443（226 aa）
Chain C
218–443（226 aa）
Chain D
218–443（226 aa）
Chain E
218–443（226 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.16 Å |
| 9MCX CRYSTAL STRUCTURE OF HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR IIA COMPLEX H131 VARIANT Deposited 2024-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；25% PEG 2000 MME, 0.1 M HEPES pH 7.5
|
Resolution 2.38 Å R-free 0.234 |
| 9MCY CRYSTAL STRUCTURE OF HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR IIA COMPLEX R131 VARIANT Deposited 2024-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；10% PEG 5000 MME, 12% isopropanol , 0.1 M MES pH 6.5
|
Resolution 2.85 Å R-free 0.236 |
| 9MCY CRYSTAL STRUCTURE OF HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR IIA COMPLEX R131 VARIANT Deposited 2024-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
227–449（223 aa）
Chain D
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；10% PEG 5000 MME, 12% isopropanol , 0.1 M MES pH 6.5
|
Resolution 2.85 Å R-free 0.236 |
| 9OUV Crystal structure of human IGG1 FC fragment-FC-gamma receptor IIB complex Deposited 2025-05-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；150 mM sodium chloride
100 mM Tris-HCl pH 8.0
8% PEG 6000
|
Resolution 3.07 Å R-free 0.241 |
| 9UO5 Cryo-EM structure of the human IgG-Fc hexamer Deposited 2025-04-25 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
218–443（226 aa）
Chain B
218–443（226 aa）
Chain C
218–443（226 aa）
Chain D
218–443（226 aa）
Chain E
218–443（226 aa）
Chain F
218–443（226 aa）
Chain G
218–443（226 aa）
Chain H
218–443（226 aa）
Chain I
218–443（226 aa）
Chain J
218–443（226 aa）
Chain K
218–443（226 aa）
Chain L
218–443（226 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.75 Å |
| 9UOK Structure of the complex of LGR4_ECD with Norrin Deposited 2025-04-25 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
220–449（230 aa）
Chain F
220–449（230 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.05 Å |
105 other PDB entries and 128 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | IGG1_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–221； UniProt 223–443 Author chain B； PDBConstruct 1–221； UniProt 223–443 Author chain C； PDBConstruct 1–221； UniProt 223–443 Author chain D； PDBConstruct 1–221； UniProt 223–443 Author chain E； PDBConstruct 1–221； UniProt 223–443 Author chain F； PDBConstruct 1–221； UniProt 223–443 Author chain G； PDBConstruct 1–221； UniProt 223–443 Author chain H； PDBConstruct 1–221； UniProt 223–443 Author chain I； PDBConstruct 1–221； UniProt 223–443 Author chain J； PDBConstruct 1–221； UniProt 223–443 Author chain K； PDBConstruct 1–221； UniProt 223–443 Author chain L； PDBConstruct 1–221； UniProt 223–443 |
